{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-050335","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.782451+00:00","generated_at":"2026-06-03T12:06:45.999442+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M","bullets":["ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.","Net loss $17.7M vs $12.3M loss in Q1 2023; cash and investments $213.6M, no debt outstanding.","Raises 2024 ARCALYST net product revenue guidance to $370-390M from prior $360-380M.","Plans to initiate abiprubart Phase 2b trial in Sjögren's Disease in second half of 2024.","About 2,000 prescribers have written ARCALYST since launch; average therapy duration ~23 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-050335","json":"https://secwatch.observer/filing/0001104659-24-050335.json","markdown":"https://secwatch.observer/filing/0001104659-24-050335.md","text":"https://secwatch.observer/filing/0001104659-24-050335.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/0001104659-24-050335-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/tm2412282d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:06:45.999442+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"902dc4727f2cf210f10921be8dd16c2332afaf83","claim":"Kiniksa Pharmaceuticals International, plc reported first quarter 2024 results: revenue Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023., net income Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter. Guidance raised.","evidence_excerpt":"On April 23, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924050335/0001104659-24-050335-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Revenue","value":"Total revenue for the first quarter of 2024 was $79.9 million, compared to $48.3 million for the first quarter of 2023."},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $17.7 million, compared to a net loss of $12.3 million for the first quarter"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}